Breaking News Instant updates and real-time market news.

JD

JD.com

$27.99

-0.76 (-2.64%)

, QCOM

Qualcomm

$56.71

-1.05 (-1.82%)

07:35
03/25/19
03/25
07:35
03/25/19
07:35

Unusual call flow in option market yesterday

Notable call activity was cited Friday in JD.com (JD), Qualcomm (QCOM), Twitter (TWTR), Citi (C), Caesars (CZR), Activision Blizzard (ATVI), Tencent (TME), Marathon Oil (MRO), United Continental (UAL), and Splunk (SPLK).

JD

JD.com

$27.99

-0.76 (-2.64%)

QCOM

Qualcomm

$56.71

-1.05 (-1.82%)

TWTR

Twitter

$32.98

0.37 (1.13%)

C

Citi

$60.98

-2.92 (-4.57%)

CZR

Caesars

$8.68

-0.21 (-2.36%)

ATVI

Activision Blizzard

$46.70

-1.9 (-3.91%)

TME

Tencent Music

$16.85

-0.59 (-3.38%)

MRO

Marathon Oil

$16.68

-1.01 (-5.71%)

UAL

United Airlines

$80.09

-0.89 (-1.10%)

SPLK

Splunk

$125.68

-6.8 (-5.13%)

  • 26

    Mar

  • 27

    Mar

  • 04

    Apr

  • 15

    Apr

  • 16

    Apr

  • 16

    Apr

  • 23

    Apr

  • 01

    May

  • 09

    Jul

JD JD.com
$27.99

-0.76 (-2.64%)

03/01/19
BNCH
03/01/19
NO CHANGE
Target $34
BNCH
Buy
JD.com price target raised to $34 after 'solid quarter' at Benchmark
Benchmark analyst Fawne Jiang said JD.com reported "solid" Q4 results, with upside driven by healthy core e-commerce growth as well as improving margin trends. Despite ongoing macro concerns, Q1 revenue guidance and full year margin guidance were above expectations, said Jiang, who raised her price target on JD.com shares to $34 from $31 and keeps a Buy rating on the stock.
03/01/19
LYON
03/01/19
UPGRADE
Target $31
LYON
Outperform
JD.com upgraded to Outperform from Underperform at CLSA
CLSA analyst Elinor Leung upgraded JD.com to Outperform from Underperform after the company reported "weak," but better than expected, top-line growth in Q4 along with a margin beat on better cost control. 2019 margins are expected to improve further, noted Leung, who raised the firm's price target on JD.com shares to $31 from $24.
01/31/19
UBSW
01/31/19
DOWNGRADE
UBSW
Neutral
JD.com downgraded to Neutral from Buy at UBS
01/14/19
BERN
01/14/19
INITIATION
Target $16
BERN
Market Perform
JD.com assumed with a Market Perform at Bernstein
Bernstein analyst David Dai assumed coverage on JD with a Market Perform and $16 price target.
QCOM Qualcomm
$56.71

-1.05 (-1.82%)

01/31/19
BMOC
01/31/19
NO CHANGE
Target $54
BMOC
Market Perform
Qualcomm price target lowered to $54 from $60 at BMO Capital
BMO Capital analyst Tim Long lowered his price target on Qualcomm to $54 and kept his Market Perform rating after its mixed Q4 results, with the top-line miss driven by weaker chip and royalty revenues being offset by an earnings beat due to lower operating expense and a $150M Huawei payment. The analyst also sees growing uncertainty for the stock from the weak China smartphone market and heating up litigation activity.
03/04/19
SUSQ
03/04/19
NO CHANGE
SUSQ
Positive
Cirrus Logic, Qualcomm winners in S10 teardown, Knowles loser, says Susquehanna
Susquehanna analyst Christopher Rolland disassembled the Korean version of Samsung's (SSNLF) Galaxy S10 and he found Cirrus Logic (CRUS) won the new amplifier sockets as well as maintaining their codec in the Exynos version. The analyst found Qualcomm (QCOM) has won the under-glass fingerprint sensor, apparently for all designs, not just those using a Qualcomm AP. He said this is a new source of revenue for Qualcomm. He noted the big loser was Knowles (KN) because traditionally Samsung used microphone MEMS from Knowles but in the GS10 not one but two microphones are supplied by GoerTek.
01/31/19
MZHO
01/31/19
NO CHANGE
Target $62
MZHO
Buy
Qualcomm price target lowered to $62 from $66 at Mizuho
Mizuho analyst Vijay Rakesh lowered his price target for Qualcomm to $62 saying the company reported a slightly below consensus December quarter but guided to an in-line March quarter. Handsets remain in a slowdown, Rakesh tells investors in a research note. However, he keeps a Buy rating on Qualcomm as the company "awaits some critical litigations and the 2020 5G ramp."
02/26/19
STFL
02/26/19
NO CHANGE
Target $57
STFL
Hold
Qualcomm legal overhang limits upside despite 5G leadership, says Stifel
After Qualcomm's "barrage" of product announcements timed for Mobile World Congress this week, Stifel analyst Kevin Cassidy said he believes the company most notable announcements were its second generation 5G modem and second generation RF Front-End solutions. While he sees Qualcomm as the clear leader in 5G modem technology, Cassidy noted that significant 5G modem related revenue may be two years away and he believes the legal overhang of the recently concluded FTC trial limits Qualcomm's share price upside. Cassidy, who thinks Qualcomm shares could trade in a range of about $30 to $90 depending on the outcome of the legal disputes, keeps a Hold rating and $57 price target on the stock.
TWTR Twitter
$32.98

0.37 (1.13%)

02/08/19
SRCH
02/08/19
DOWNGRADE
SRCH
Hold
Twitter downgraded to Hold from Buy at Summit Insights
02/08/19
MKMP
02/08/19
NO CHANGE
Target $43
MKMP
Buy
MKM Partners sees no change to Twitter's improving fundamentals
MKM Partners analyst Rob Sanderson kept his Buy rating and $43 price target on Twitter after its Q4 results. The analyst says that while earnings and revenues produced "meaningful upside", the decline in Twitter stock price was driven by the "disappointing DAU disclosure and expense guidance." Sanderson further contends that while the quarter marks a reset in expectations, he sees "no change to strong and improving underlying fundamentals at Twitter".
02/14/19
SBSH
02/14/19
NO CHANGE
SBSH
Alphabet is now Citi's top Internet pick, replacing Amazon.com
Citi analyst Mark May shuffled his U.S. Internet rankings, moving Alphabet (GOOGL) up to his top pick, replacing Amazon.com (AMZN). Alphabet is followed by Netflix (NFLX) and Facebook (FB). The stocks moving up in May's ranking include Alphabet, Facebook, eBay (EBAY), TripAdvisor (TRIP), Snap (SNAP) and Twitter (TWTR), while those moving down include Amazon and Yelp (YELP).
02/13/19
BTIG
02/13/19
NO CHANGE
Target $42
BTIG
Buy
Twitter price target raised to $42 from $30 at BTIG
BTIG analyst Richard Greenfield raised his price target on Twitter to $42 and kept his Buy rating, sayings its product is getting better as seen in the continued strong growth in daily active user trends. The analyst adds that the news cycle remains a "strong tailwind" behind interest in Twitter, and with only 40% of monthly users logging on daily, Greenfield sees "significant headroom" for the platform to grow usage in the next several years.
C Citi
$60.98

-2.92 (-4.57%)

01/16/19
01/16/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Citi (C) downgraded to Hold from Buy at Standpoint Research. 2. Snap (SNAP) downgraded to Sector Perform from Outperform at RBC Capital with analyst Mark Mahaney citing the company's recent "mixed" pre-announcement and, more importantly, its latest disclosure of a "surprise" exit by its CFO Tim Stone who was on the job for less than a year. 3. Nordstrom (JWN) downgraded to Neutral from Conviction Buy at Goldman Sachs, to Neutral from Overweight at Atlantic Equities, and to Market Perform from Outperform at Telsey Advisory. 4. AB InBev (BUD) downgraded to Underperform from Hold at Jefferies with analyst Edward Mundy saying market share pressures, some of which have only recently become visible, will likely persist, and could lead to disappointment against high expectations of an emerging-led recovery. 5. HP Enterprise (HPE) downgraded to Equal Weight from Overweight at Morgan Stanley, while NetApp (NTAP) was downgraded to Underweight from Equal Weight. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/25/19
OPCO
01/25/19
NO CHANGE
OPCO
Outperform
Bank stocks still 'resoundingly cheap,' says Oppenheimer
Oppenheimer analyst Chris Kotowski told investors in a research note that one reason he is so "incessantly bullish" on bank stocks is that investors "still so incessantly hate them." The stocks still remain resoundingly cheap at a 63% relative P/E multiple even though bank balance sheets are arguably the best they have ever been, and the business models decidedly less capital-intensive, he contends. He continues to recommend Outperform-rated Bank of America (BAC), CIT (CIT), Citi (C), Goldman (GS), Jefferies (JEF), Morgan Stanley (MS) and U.S. Bancorp (USB).
02/22/19
JEFF
02/22/19
UPGRADE
Target $73
JEFF
Buy
Citi upgraded to Buy from Hold at Jefferies
Jefferies analyst Kenneth Usdin upgraded Citi to Buy and raised his price target for the shares to $73 from $64.
02/22/19
JEFF
02/22/19
UPGRADE
Target $73
JEFF
Buy
Jefferies sees positive risk/reward on Citi, upgrades shares to Buy
Jefferies analyst Ken Usdin upgraded Citi to Buy from Hold and raised his price target for the shares to $73 from $64. The analyst believes Citi's 2019 will show better revenue growth, stable costs and credit trends, as well as $20B-plus of capital returns. He believes the stock's risk/reward is "skewed to the positive," especially if Citi starts showing tangible progress toward its 13.5% ROTCE goal for 2020. Further, the Mexico and Latin America "story adds to Citi growth/return profile," Usdin tells investors in a research note.
CZR Caesars
$8.68

-0.21 (-2.36%)

03/20/19
JPMS
03/20/19
NO CHANGE
Target $60
JPMS
Overweight
Eldorado shares could be worth $72-$80 with Caesars deal, says JPMorgan
JPMorgan analyst Daniel Politzer estimates that an Eldorado Resorts (ERI) acquisition of Caesars Entertainment (CZR) could generate $300M in synergies, imply a valuation of $72-$80 per share, and be ~50% accretive on a free cash flow per share basis. Reuters reported over the weekend that the two companies are in merger talks. The analyst's scenario contemplates Eldorado acquiring Caesars for $10.50 per share, or a 23% premium to last night's close, with the offer consisting of $6.25 in cash and $4.25 worth of stock. Politzer keeps an Overweight rating on Eldorado Resorts with a $60 price target.
03/20/19
FBCO
03/20/19
INITIATION
Target $13
FBCO
Outperform
Caesars assumed with an Outperform at Credit Suisse
Credit Suisse analyst Ben Combes assumed coverage of Caesars with an Outperform rating and $13 price target.
01/16/19
BOFA
01/16/19
DOWNGRADE
Target $9
BOFA
Neutral
Caesars downgraded to Neutral following rally at BofA/Merrill
BofA/Merrill analyst Shaun Kelley downgraded Caesars to Neutral from Buy and lowered its price target to $9. Kelley is using the rally year-to-date in shares to downgrade saying he is more cautious longer-term towards Las Vegas pricing power and growth.
01/18/19
MSCO
01/18/19
NO CHANGE
MSCO
Overweight
Morgan Stanley prefers Las Vegas to Macau in gaming entering 2019
Morgan Stanley analyst Thomas Allen said he is confident that the Las Vegas outlook is better than perceived after Q4 appears to have shown a meaningful rebound, noting also that his convention tracker supports strong 2019 demand growth and that flight capacity to the market is growing. Meanwhile, as a firm, Morgan Stanley has cut its Macau market gaming revenue outlook and industry view, Allen noted. Combining his Las Vegas outlook and bullish stance on regional U.S. gaming, Allen called MGM Resorts (MGM) and Caesars (CZR) his preferred large cap gaming stocks entering 2019, stating that he believes expectations for both are beatable. He reiterates Overweight ratings on both, as well as on Las Vegas Sands (LVS), and keeps an Equal Weight rating on Wynn Resorts (WYNN).
ATVI Activision Blizzard
$46.70

-1.9 (-3.91%)

03/15/19
PIPR
03/15/19
NO CHANGE
Target $52
PIPR
Overweight
Activision worth a look after 50% drop in six months, says Piper Jaffray
Activision Blizzard shares are down nearly 50% in the past six months and investors should be "kicking the tires," given an improving setup in late 2019 and 2020, Piper Jaffray analyst Michael Olson tells investors in a research note. The analyst sees five reasons to do the work on Activision, including: increasing near-term talk on streaming, potential E3 announcements, anticipation around improving fundamentals in 2020, management's re-allocation of resources towards key franchises, and valuation. While it may still be early with a lack of new game catalysts in 2019, patient investors should consider "chipping away at a position" in the stock at current levels, Olson writes. He maintains an Overweight rating on Activision Blizzard with a $52 price target.
03/19/19
MSCO
03/19/19
NO CHANGE
Target $55
MSCO
Overweight
Morgan Stanley lays out ways Call of Duty Mobile matters for Activision Blizzard
After Activision Blizzard announced that "Call of Duty: Mobile" will be launching in the Americas, Europe and elsewhere with a public beta coming this summer, Morgan Stanley analyst Brian Nowak listed four reasons he sees for why the game "matters." Namely, he sees CoD: Mobile as a way for the company to capitalize on its leading intellectual property in the rapidly growing free-to-play and mobile markets; he noted that there are multiple annual billion dollar revenue games in China alone, noting that even a $500M revenue mobile franchise would add 9% to 2020 EPS; he said he doesn't have the game in his model, meaning its "all optionatlity"; and he views the game as another opportunity to prove Call of Duty is still a AAA franchise. Nowak keeps an Overweight rating and $55 price target on Activision Blizzard shares.
03/19/19
BARD
03/19/19
NO CHANGE
BARD
Stadia announcement positive for Google and game publishers, says Baird
Following Google's (GOOGL) announcement of details on it's cloud video game streaming platform, "Stadia," Baird analyst Colin Sebastian said he views the announcement as positive both for Google and for game publishers such as Activision Blizzard (ATVI), Electronic Arts (EA) and Take-Two (TTWO). The gaming platform has "impressive technical capabilities" and will support third-party game development, noted Sebastian, who added that he views the hiring of Jade Raymond as a sign Google sees significant long-term opportunity in digital entertainment.
03/21/19
03/21/19
NO CHANGE

SunTrust says reviews of Activision Blizzard's Sekiro 'extremely strong'
SunTrust analyst Matthew Thornton maintained a Buy rating on Activision Blizzard ahead of the company's Friday release of Sekiro. The analyst noted that reviews for Sekiro have been "extremely strong," which he said was a positive datapoint for Q1, as the firm's model assumes only 1M units for Sekiro.
TME Tencent Music
$16.85

-0.59 (-3.38%)

02/12/19
02/12/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Viavi (VIAV) initiated with an Outperform at Northland. 2. CECO Environmental (CECE) initiated with a Buy at B. Riley FBR. 3. Tencent Music (TME) initiated with an Outperform at Macquarie. 4. Enable Midstream (ENBL) initiated with a Neutral at Mizuho. 5. Elanco (ELAN) initiated with a Market Perform at William Blair. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
02/12/19
MACQ
02/12/19
INITIATION
MACQ
Outperform
Tencent Music initiated with an Outperform at Macquarie
01/18/19
01/18/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Tencent Music (TME) initiated with a Buy at HSBC. 2. Wex (WEX) and FleetCor (FLT) were initiated with a Buy at BTIG. 3. Joint Corp (JYNT) initiated with a Buy at DA Davidson. 4. York Water (YORW) initiated with a Buy at Janney Montgomery Scott. 5. Primerica (PRI) initiated with an Outperform at Credit Suisse. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
03/20/19
FBCO
03/20/19
DOWNGRADE
FBCO
Neutral
Tencent Music downgraded to Neutral from Outperform at Credit Suisse
Credit Suisse downgraded Tencent Music to Neutral from Outperform citing valuation.
MRO Marathon Oil
$16.68

-1.01 (-5.71%)

03/05/19
JPMS
03/05/19
NO CHANGE
Target $25
JPMS
Overweight
Marathon Oil price target raised to $25 from $23 at JPMorgan
Since 2016, ConocoPhillips (COP) has been the best performing Major Oil stock as well as one of the best stocks in the entire energy sector on its proven capital allocation strategy and strong execution, JPMorgan analyst Arun Jayaram tells investors in a research note. He sees similar attributes at Marathon Oil (MRO). The company's organic break-even after dividend coverage of $45 per barrel "stacks up solidly" against ConocoPhillips given its low double digit oil growth profile, adds the analyst. He believes Marathon Oil have the potential to perform well on a relative basis as the market continues to value free cash flow generation and cash return over growth at conservative oil prices. Jayaram reiterates an Overweight rating on the name.
12/17/18
RHCO
12/17/18
INITIATION
Target $25
RHCO
Buy
Marathon Oil initiated with a Buy at SunTrust
SunTrust analyst Neal Dingmann started Marathon Oil with a Buy rating and $25 price target, citing the company's "notable" year over year operational improvements and its favorable pricing. He also cites Marathon's buyback and dividend plans.
12/21/18
SBSH
12/21/18
UPGRADE
SBSH
Buy
Marathon Oil upgraded to Buy from Neutral at Citi
Citi analyst Robert Morris upgraded Marathon Oil to Buy from Neutral.
01/09/19
SOCO
01/09/19
DOWNGRADE
SOCO
Equalweight
Marathon Oil downgraded to Equalweight from Overweight at Capital One
UAL United Airlines
$80.09

-0.89 (-1.10%)

02/22/19
STPT
02/22/19
DOWNGRADE
STPT
Hold
United Continental downgraded to Hold from Buy at Standpoint Research
03/01/19
DBAB
03/01/19
DOWNGRADE
DBAB
Hold
Deutsche downgrades American Airlines, Delta on global market exposure
Deutsche Bank analyst Michael Linenberg downgraded both American Airlines (AAL) and Delta Air Lines (DAL) to Hold from Buy. Recent global macro data points "have been less encouraging of late" suggesting that airline industry risks are now more biased to the downside, Linenberg tells investors in a research note. As a result, the analyst is finding it more difficult to advocate "new money" positions in names with the most exposure to global markets. This drives his downgrade of both American and Delta to Hold. Linenberg lowered his price target for American to $40 from $47 and for Delta to $55 from $66. He also lowered his target for Buy-rated Alaska Air (ALK) to $73 from $75, for Buy-rated Allegiant Travel (ALGT) to $160 from $169, for Buy-rated JetBlue (JBLU) to $20 from $22, for Buy-rated SkyWest (SKYW) to $68 from $75, for Buy-rated Spirit Airlines (SAVE) to $75 from $79, for United Continental (UAL) to $105 from $109, and for Buy-rated Mesa Air (MESA) to $17 from $18.
03/13/19
MSCO
03/13/19
NO CHANGE
MSCO
Morgan Stanley says 737 MAX grounding shouldn't hurt long-term fundamentals
Morgan Stanley analyst Rajeev Lalwani noted that most major countries and airlines that operate Boeing's (BA) 737 MAX, except for the U.S. and Canada, have placed restrictions around the plane and his expectation is for a grounding of the fleet globally. In that base case, he said there is likely to be disruption to Boeing's deliveries and order activity that ultimately create a buying opportunity over the coming quarters as he thinks the issue should not impact fundamentals in the long run. In regard to suppliers such as Spirit AeroSystems (SPR) and United Technologies (UTX), Lalwani believes disruption will be limited, contrary to market reactions. Among U.S. airlines who operate the 737 MAX, Lalwani said Southwest (LUV) screens as most exposed versus American Airlines (AAL) and United Continental (UAL). For aircraft lessors like Air Lease (AL) and AerCap (AER), a global grounding scenario has "mixed implications," added the analyst. Though he remains comfortable with his Overweight rating and $500 price target on Boeing shares, Lalwani thinks clarity on the path ahead for the 737 will be needed for shares to resume their upward trend.
03/15/19
IMPC
03/15/19
NO CHANGE
Target $78
IMPC
Underperform
United Continental shares offer unfavorable risk/reward, says Imperial Capital
Imperial Capital analyst Michael Derchin says shares of United Continental Holdings (UAL) offer an unfavorable risk/reward opportunity at current levels. United's unit revenue momentum is likely to slow meaningfully and possibly inflect to negative territory by the second half of 2019, Derchin tells investors in a research note. The shares are trading at nearly a 40% premium to American Airlines (AAL) on fiscal 2020 earnings estimates despite relatively similar margin outlooks, adds the analyst. He keeps an Underperform rating on United Continental with a $78 price target.
SPLK Splunk
$125.68

-6.8 (-5.13%)

03/01/19
BMOC
03/01/19
NO CHANGE
Target $162
BMOC
Outperform
Splunk price target raised to $162 from $132 at BMO Capital
BMO Capital analyst Keith Bachman raised his price target on Splunk to $162 and kept his Outperform rating. The analyst expects the demand momentum to continue to drive the stock higher while its use cases continues to increase. Bachman also sees multiple avenues for its total addressable market expansion that include Security and Internet of Things and contends that Splunk valuation is attractive relative to its growth rate.
03/08/19
ARGS
03/08/19
NO CHANGE
Target $156
ARGS
Buy
Splunk price target raised to $156 from $135 at Argus
Argus analyst Joseph Bonner raised his price target on Splunk to $156 and kept his Buy rating, saying that in spite of its Q4 earnings beat and raised FY20 revenue outlook, the stock has fallen since reporting results last week. The analyst contends however that shares have "room to run" given Splunk's "strong revenue growth in a rapidly expanding big data analytics market." Bonner also sees the company as a potential acquisition target for a larger enterprise software firm, while raising his FY20 EPS forecast to $1.68 from $1.60 given its growth trends.
03/13/19
MZHO
03/13/19
INITIATION
Target $150
MZHO
Buy
Splunk initiated with a Buy at Mizuho
Mizuho analyst Gregg Moskowitz initiated Splunk with a $150 price target.
03/14/19
MZHO
03/14/19
INITIATION
Target $150
MZHO
Buy
Mizuho sees 'very healthy' duration-adjusted growth for Splunk, starts at Buy
Mizuho analyst Gregg Moskowitz last night initiated coverage of Splunk with a Buy rating and $150 price target. The company's value proposition "remains significantly differentiated," and it is "very well-positioned" to continue growing at a high rate, Moskowitz tells investors in a research note. Contrary to the bear thesis, Splunk's duration-adjusted growth is "very healthy," adds the analyst.

TODAY'S FREE FLY STORIES

MNK

Mallinckrodt

$3.40

0.015 (0.44%)

12:15
12/07/19
12/07
12:15
12/07/19
12:15
Hot Stocks
Mallinckrodt presents data on infantile spasms predictive model »

Mallinckrodt announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

STOK

Stoke Therapeutics

$28.91

3.99 (16.01%)

12:13
12/07/19
12/07
12:13
12/07/19
12:13
Hot Stocks
Stoke Therapeutics presents preclinical data from studies of STK-001 »

Stoke Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APTO

Aptose Biosciences

$2.55

-0.04 (-1.54%)

12:11
12/07/19
12/07
12:11
12/07/19
12:11
Hot Stocks
Aptose reports CG-806 data in patients with chronic lymphocytic leukemia »

Aptose Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EPZM

Epizyme

$18.22

2.9 (18.93%)

10:09
12/07/19
12/07
10:09
12/07/19
10:09
Hot Stocks
Epizyme announces 'positive, mature data' for Phase 2 trial of tazemetostat »

Epizyme reported…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 18

    Dec

  • 23

    Jan

PRNB

Principia Biopharma

$37.30

0.86 (2.36%)

10:07
12/07/19
12/07
10:07
12/07/19
10:07
Hot Stocks
Principia Biopharma announces 'consistent positive data' for PRN1008 »

Principia Biopharma…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$200.99

1.64 (0.82%)

, GOOGL

Alphabet Class A

$1,339.41

11.6 (0.87%)

09:31
12/07/19
12/07
09:31
12/07/19
09:31
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

FB

Facebook

$200.99

1.64 (0.82%)

GOOGL

Alphabet Class A

$1,339.41

11.6 (0.87%)

GOOG

Alphabet

$1,341.23

12.23 (0.92%)

AAPL

Apple

$270.71

5.15 (1.94%)

AMZN

Amazon.com

$1,750.79

10.2 (0.59%)

SQ

Square

$68.00

0.85 (1.27%)

TWTR

Twitter

$30.19

0.16 (0.53%)

CSIQ

Canadian Solar

$18.35

0.39 (2.17%)

FSLR

First Solar

$53.36

1.06 (2.03%)

JASO

JA Solar

$0.00

(0.00%)

SPWR

SunPower

$7.23

0.15 (2.12%)

TSL

Trina Solar

$0.00

(0.00%)

YGE

Yingli Green Energy

$0.00

(0.00%)

AKS

AK Steel

$3.24

0.065 (2.05%)

MT

ArcelorMittal

$17.88

0.43 (2.46%)

NUE

Nucor

$57.60

1.13 (2.00%)

STLD

Steel Dynamics

$35.10

0.67 (1.95%)

TMST

TimkenSteel

$6.90

0.41 (6.32%)

X

U.S. Steel

$13.95

0.615 (4.61%)

AA

Alcoa

$20.60

0.68 (3.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 10

    Dec

  • 06

    Feb

  • 26

    Feb

FATE

Fate Therapeutics

$13.64

0.07 (0.52%)

09:27
12/07/19
12/07
09:27
12/07/19
09:27
Hot Stocks
Fate Therapeutics reports initial clinical data for FT516 and FT50 »

Fate Therapeutics …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

09:25
12/07/19
12/07
09:25
12/07/19
09:25
Conference/Events
JPMorgan enterprise software analyst to hold an analyst/industry conference call »

Software Analyst Murphy,…

CRVS

Corvus Pharmaceuticals

$4.26

-0.36 (-7.79%)

09:23
12/07/19
12/07
09:23
12/07/19
09:23
Hot Stocks
Corvus reports initial results from Phase 1/1b trial of CPI-818 »

Corvus Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KPTI

Karyopharm

$16.30

-1.15 (-6.59%)

09:21
12/07/19
12/07
09:21
12/07/19
09:21
Hot Stocks
Karyopharm announces updated Xpovio data in multiple myeloma »

Karyopharm Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

ABBV

AbbVie

$86.97

0.3 (0.35%)

09:18
12/07/19
12/07
09:18
12/07/19
09:18
Hot Stocks
AbbVie reports results of 7.5-year pooled analysis of Imbruvica »

AbbVie announced results…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

SRRA

Sierra Oncology

$0.49

0.1035 (27.13%)

09:16
12/07/19
12/07
09:16
12/07/19
09:16
Hot Stocks
Sierra Oncology reports new analyses of momelotinib compared to ruxolitinib »

Sierra Oncology reported…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 08

    Dec

SGMO

Sangamo

$11.65

0.05 (0.43%)

, PFE

Pfizer

$38.29

0.26 (0.68%)

09:14
12/07/19
12/07
09:14
12/07/19
09:14
Hot Stocks
Sangamo, Pfizer announce follow-up results from Phase 1/2 hemophilia A.study »

Sangamo Therapeutics…

SGMO

Sangamo

$11.65

0.05 (0.43%)

PFE

Pfizer

$38.29

0.26 (0.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Dec

  • 11

    Dec

VSTM

Verastem

$1.31

0.055 (4.38%)

09:12
12/07/19
12/07
09:12
12/07/19
09:12
Hot Stocks
Verastem announces 62% response rate for duvelisib in T-cell lymphoma »

Verastem announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

RHHBY

Roche

$0.00

(0.00%)

09:09
12/07/19
12/07
09:09
12/07/19
09:09
Hot Stocks
Genentech announces new data on CD20-CD3 T-cell in Hodgkin's lymphoma »

Genentech, a member of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Dec

  • 10

    Dec

  • 10

    Dec

  • 16

    Dec

XENE

Xenon Pharmaceuticals

$13.92

0.03 (0.22%)

, BMRN

BioMarin

$79.90

-0.18 (-0.22%)

08:59
12/07/19
12/07
08:59
12/07/19
08:59
Hot Stocks
Xenon to provide updates on partnered epilepsy programs »

Xenon Pharmaceuticals…

XENE

Xenon Pharmaceuticals

$13.92

0.03 (0.22%)

BMRN

BioMarin

$79.90

-0.18 (-0.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

CLF

Cleveland-Cliffs

$8.14

0.2 (2.52%)

, AKS

AK Steel

$3.24

0.065 (2.05%)

08:56
12/07/19
12/07
08:56
12/07/19
08:56
Recommendations
Cleveland-Cliffs, AK Steel analyst commentary  »

Cleveland-Cliffs shares…

CLF

Cleveland-Cliffs

$8.14

0.2 (2.52%)

AKS

AK Steel

$3.24

0.065 (2.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

M

Macy's

$15.15

0.04 (0.26%)

08:53
12/07/19
12/07
08:53
12/07/19
08:53
Periodicals
Barron's skeptical on Macy's shares into the holiday season »

The turnaround at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COF

Capital One

$101.39

1.8 (1.81%)

08:43
12/07/19
12/07
08:43
12/07/19
08:43
Periodicals
Capital One shares could have more upside ahead, Barron's says »

Shares of Capital One…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

EXPE

Expedia

$107.58

1.9 (1.80%)

08:26
12/07/19
12/07
08:26
12/07/19
08:26
Periodicals
Expedia shares still a buy despite management changes, Barron's says »

Shares of Expedia remain…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

DAR

Darling Ingredients

$24.05

0.39 (1.65%)

, CODI

Compass Diversified

$23.88

0.45 (1.92%)

08:21
12/07/19
12/07
08:21
12/07/19
08:21
Periodicals
Darling, Qualys among small-caps to own for 2020 breakout, Barron's says »

In its weekend cover…

DAR

Darling Ingredients

$24.05

0.39 (1.65%)

CODI

Compass Diversified

$23.88

0.45 (1.92%)

QLYS

Qualys

$85.37

-0.37 (-0.43%)

LECO

Lincoln Electric

$92.52

0.69 (0.75%)

HASI

Hannon Armstrong

$29.50

0.24 (0.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 12

    Dec

CBMG

Cellular Biomedicine

$17.56

0.18 (1.04%)

08:11
12/07/19
12/07
08:11
12/07/19
08:11
Hot Stocks
Cellular Biomedicine presents first clinical data of C-CAR088 in myeloma »

Cellular Biomedicine…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

AXLA

Axcella

$3.63

-0.83 (-18.61%)

08:07
12/07/19
12/07
08:07
12/07/19
08:07
Hot Stocks
Axcella says preclinical of AXA4010 data show multifactorial potential »

Axcella Health announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AZN

AstraZeneca

$47.68

0.06 (0.13%)

08:04
12/07/19
12/07
08:04
12/07/19
08:04
Hot Stocks
AstraZeneca says Calquence combination improved survival in leukemia patients »

AstraZeneca presented…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Dec

ABBV

AbbVie

$86.97

0.3 (0.35%)

08:01
12/07/19
12/07
08:01
12/07/19
08:01
Hot Stocks
AbbVie announces follow-up data from chronic lymphocytic leukemia study »

AbbVie announced results…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.